High Risk Myelodysplastic syndrome

N.Dahmaoui, M.Lamchahab, S.Douma, B.Fatih, B.Oukkach*, M.Rachid, M.Qachouh, S.Cherkaoui, N.Khoubila, A.Madani
Department of hematology and pediatric oncology
* Hematology laboratory
CHU Ibn Rochd
Faculty of medicine and pharmacy Casablanca
University Hassan II Casablanca

Introduction

Myelodysplastic syndromes consist of clonal bone marrow diseases associated with ineffective hematopoiesis.

High risk Myelodysplastic syndromes are characterized by a frequent evolution into acute leukemia.

the incidence of MDS in morocco is 2% of all malignant hemopathies.

Objective

The main objective of our study is to determine the incidence of high-risk myelodysplastic syndromes in the general population in Morocco.


Patients & Methods

Study description	
Study	Descriptive retrospective
Department	Clinical hematology CHU Ibn Rochd Casablanca
Term	January 2004 to December 2018
Population	patients diagnosed with high risk MDS
Diagnosis tools	blood count , blood film,myelogram,karyotype
Scoring	IPSS
Exclusion Criteria	MDS/MPS border syndromes,AML with a blast rate >20% at diagnosis


Results

Study results	
Patient number	34/271
Average age	59,9 (31-88)
Sexe ratio M/F	0,74
Frequency of cases/year	2,5
Genetic predisposition	1%
Diagnosis median time	3 months

IPSS according to age




Clinical features



Biological characteristics	N	%
HB< 10	34	100%
PNN<1800	14	41%
PQ<100000	20	58,90%
Blood film	6	17,64%
Cytopenia number		
1	10	29,41%
2	12	35,29%
3	12	35,29%
OMB	10	29,41%

Symptomatic treatment		
Treatment	Patients number (n=34)	Percentage %
Red blood cell transfusion	32	94%
Transfusion in platelet units	7	20,18%
Iron chelators	1	3%
Antibiotic	7	20,18%

Disease course





Conclusion

Our results agree with the studies published in the literature with regard to epidemiology, incidence, clinic, prognosis, and symptomatic treatment, but there are some discrepancies in terms of specific treatment and global survival. The main complication detected in our series was transformation into acute leukemia.

MDS remains an underestimated and underdiagnosed pathology.
Diagnostic limit: incomplete assessment, cytogenetic contribution.

References

[1] P Fenaux , Groupe francophone des myélodysplasies (GFM). Consensus français sur les syndromes myélodysplasiques (SMD) et la leucémie myélomonocytaire chronique : Diagnostic, classifications, traitement, Mise à jour 2015

[2] Ulrich Germing, Thomas Schroeder, Jennifer Kaivers, Andrea Kündgen, Guido Kobbe & Norbert Gattermann (2019): Novel therapies in low- and high-risk myelodysplastic syndrome, Expert Review of Hematology, DOI: 10.1080/17474086.2019.1647778